Issue link: https://www.e-digitaleditions.com/i/1022930
markets Global solubility enhancement excipient market to exceed $1 billion by 2024 BUFFALO, NY—The global solu- bility enhancement excipient market is forecast to grow at a compound annual rate of 9.9 percent through 2024, reaching $1.77 billion, accord- ing to a report by Energias Market Research. The need to enhance the bioavailability of poorly water-solu- ble drugs in oral solid dosage prod- ucts and other formulations is a key factor driving market growth. Anti-psychotic drugs to dominate global orally disintegrating tablet market NEW YORK, NY—The global orally disintegrating tablet market is projected to reach $24.4 billion by 2025, growing at a compound annual rate of 10.2 percent, according to a report by Market.Biz. Anti-psychotic drugs will account for 20.3 percent of global revenue in this market during the forecast period. The report iden- tifies Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, and Conquer as major manu- facturers in this market. industry news FDA encourages new MATs for opioid use disorder SILVER SPRING, MD—The FDA issued a draft guidance to encourage the development of novel medica- tion-assisted treatment (MAT) drugs for the treatment of opioid use disor- der (OUD). The document outlines methods for how drug developers can measure and demonstrate the effectiveness and benefits of new or existing MAT products. FDA finalizes guidances on dissolution testing and elemental impurities S I L V E R S P R I N G , M D — T h e FDA published "Dissolution Testing 8 September 2018 Tablets & Capsules Visit us at Pack Expo booth #W-721